of Companies) Fiscal Year Total Ethical Drug Manufacturers OTC Drug Manufacturers Other Manufacturers Manufacturers with NHI Price listed Drugs JPMA Generic Drug Members Manufacturers 1975 1,359 330 － 666 363 410 71 … Since then, this has only become more pronounced, with some project activity expected not to kick off until very late in 2019 or even slip into 2020. How is the Indian pharma industry changing due to the Covid-19 crisis? The UK pharmaceutical industry in general has further shifted toward engaging smaller engineering companies to design and/or deliver the increasingly smaller scale capex. Those that are at concept stage are taking much longer in general to progress, with many being placed on-hold. Even though Brexit and US political uncertainty were high-profile news stories in 2018, the respondents in our study viewed them as a distant second at 11% each. Catalent acquired Juniper Pharma Services to strengthen drug development. 2019 Global Pharmaceutical Industry Pump Market Research Report with Industry Forecast 2025 and Outlook. Takeda completed it’s acquisition of Shire in early 2019, formerly headquartered in Hampshire but having more recently relocated to Dublin. Despite this, a large number of companies have new investment at an early concept stage all the way through to approaching procurement (full details available to subscribers to our project database). Despite the optimism for product innovation based on NME approvals in 2018, other issues may have a dampening effect, notably financing into the biopharmaceutical industry. Copy this link. Abc Medium. At the dawn of a new year, INN offers a preview of potential developments in the pharmaceutical market throughout 2020. Browse over 50,000 other reports on our store. Patent expiry is the pharmaceutical sector’s perennial problem. If you continue to use this site we will assume that you are happy with it. The one thing that is certain is that this trend will likely continue in 2019 as the industry looks for new ways to control costs and increase margins. Following the move of the European Medicines Agency to Amsterdam, it still remains unclear what the UK’s regulatory position will be going forward. We felt in 2007 that the Indian pharmaceutical market was poised for a clear and discernable step-up in its growth trajectory. Outlook 2019: Pharma looks medically fit for double-digit growth after years of suffering. Novartis’ decision to move away from high volume products, through their closure of the Grimsby site, toward low volume, specialist drugs is a good example of some of the changing activity in the UK pharmaceutical sector. The key drivers of growth will continue to be the United States and pharmerging markets with 4−7% and 5–8% compound annual growth, respectively. R&D remains a major growth area, mostly due to continued strong government aspirations in this area. Engineering houses are overall still very busy, albeit with many commenting that they are seeing some of the larger schemes from clients delayed. The European pharmaceutical market is expected to grow at a compound annual growth rate of 4.5 percent between 2019 and 2027. GlobalData Pharma’s 2019 industry outlook survey reveals that more than 50% of global industry respondents believe that drug pricing and reimbursement constraints will have the greatest negative impact on the pharmaceutical sector in 2019. We were seeing that the outlook for capital expenditure (capex) projects was continuing along a relatively Brexit-resistant ‘business-as-usual’ path in the UK pharma sector, as companies pressed ahead to maintain innovative drug pipelines and service global demand. We have seen capex shift slightly away from larger primary production facilities to smaller research, development and testing facilities. January 14, 2020. GlobalData believes that cost containment measures such as price and reimbursement cuts are leading to tougher market conditions for drug manufacturers and shrinking profit margins. Growth Prospects and Emerging Trends . Coming off a record-setting year for new molecular entities approved by the FDA in 2018, will the industry being able to meet a new innovation bar in 2019? In late 2018 GSK acquired TESARO, an oncology focused company based in the US to help build drug pipeline and general capability in this area. 04-06-2019. GSK also divested the Horlicks brand to Unilever as part of the same strategic review. GSK has seen changes resulting from restructuring prompted by the appointment of a new CEO. The key question for the pharmaceutical industry in 2019 is whether the innovation train will continue to roll. Both Democrats and Republicans have reacted strongly to these latest increases and it could be an opportunity for bipartisanship to bring the cost of prescription drugs down. Save. Facebook; Twitter; Share View more share options. Investment plans were moving through the pipeline and major investors were making decisions. The Economist Intelligence Unit's healthcare, pharmaceuticals and medical devices service offers in-depth analysis, data and forecasts The larger schemes however will take some time to get going, with many not reaching the procurement phase until 2020. The pharmaceutical industry in the United Kingdom directly employs around 73,000 people and despite the continuing uncertainty around Brexit, UK pharma is thriving and investment is looking positive for 2019. Major decisions are either being delayed or placed on hold to a much greater degree. Despite concerns about a trade war between the US and China, it is not a surprise that China is still viewed as a huge market opportunity for the pharmaceutical industry. Valeo Foods confectionery deal to boost sales to €1.2bn https://t.co/GhRxgm5rvW https://t.co/2sggOpAAnO 04:43 PM Jan 15th from @ProtelProjects, Pharmaceutical Industry Outlook – France, Belgium & Netherlands – 2020. Print. The pharmaceutical sector is at a crossroads. The average price increase was about 6.3% and includes branded as well as generic drugs. Share this post. World Preview 2019, Outlook to 2024 The twelfth edition of EvaluatePharma’s World Preview brings together many of our analyses to provide a top level insight, from the world’s financial markets, into the expected performance of the industry between now and 2024. There is plenty of opportunity available for the year ahead, but it may be that suppliers need to be flexible in the type of project opportunity they target and prioritise. 04-04-2019. 5-Dec-2018 . As a result, the landscape is extremely competitive with a greater focus placed on cost. As such, we are starting to see a larger number of upgrades, maintenance and expansions rather than larger new-build capex projects for the year ahead. 2018 Pharmaceutical Trends and 2019 Outlook Posted January 8th, 2019 After failed repeal of Obamacare in 2017 and again in 2018, the ACA may very well be here to stay. Wayland Group of Canada has acquired Newcastle based Theros Pharma, to access the UK medical cannabis market. by [email protected] in Business, Technology; on January 17, 2021; 0. As the industry enters a new year, what will be key issues shaping the pharmaceutical industry in 2019? Sales of blockbuster drugs can fall off a cliff in the face of generic competition, but the next patent cliff may prove less severe, a factor in the European sector’s stable credit outlook . Indian pharmaceutical industry’s export to the US will get a boost as branded drugs worth US$ 55 billion will become off-patent during 2017 2019. Every segment of the pharmaceutical industry will continue to see consolidation throughout 2019. The worst case would likely involve the UK setting up a parallel system of approval which may end up delaying access to the market for new drugs or products. More on this story. As plans are altered or reassessed we expect delays to procurement for many larger capex projects, which may drag into 2020. Article March 2019 pharmaceutical M&A round-up. 18-04-2019. Other innovators will follow with transformational or bolt-on deals to secure competitive positions in specialty and rare disease indications. Unfortunately, the picture emerging is now one of delay. Suppliers need to ensure their focus is on the capex that is progressing, which is smaller-scale upgrades, improvements and R&D-focused projects. by Patricia Van Arnum, DCAT Editorial Director . Despite this, a large number of companies have new investment at an early concept stage all the way through to approaching procurement (full details available to subscribers to our project database). We use cookies to ensure that we give you the best experience on our website. COVID-19: Analysis of the Emerging Disease Landscape – March 2020, Coronavirus Disease (COVID-19): Epidemiology Analysis and Forecast – March 2020, Tech, Media, & Telecom Trends 2020 – Updated for the impact of COVID-19 – Thematic Research, M&A in TMT – 2019 round-up – Thematic Research, COVID -19 HOT TOPIC: Retailers’ response to COVID-19, Global Construction Outlook to 2024 (COVID-19 Impact), Switzerland authorises Moderna’s Covid-19 vaccine, CohBar, NIAID to assess CB5064 Analogs for Covid-19 treatment. Finally, there may be potential arising following an agreement between Chippenham based Vectura and Hikma for the global development of generic versions of GSK’s Ellipta dry powder inhaler. As the pharmaceutical regulatory … Among the geographic markets, … Worldwide X-ray Food & Pharmaceutical Inspection Equipment Market Forecast 2019-2024 Growth Drivers, Regional Outlook . Although several biosimilars are now approved in the US, the pace of their subsequent launch and market growth remains slow and most biosimilars still face stiff legal battles. This is supported by a Government announcement of a second round of industry investment in this area. We previously wrote about GSK as an example of a major player who had moved away from large-scale investment, which was expected in 2019. Statista. There are still resourcing and capacity concerns in some cases. Chart. Conversations with payers will also be a lot tougher and go beyond price to demonstration of value to specific patient sub-populations. Synopsis. The big challenge that companies will face is how to best navigate the Chinese regulatory and commercial landscape. Based on the Pharmaceutical industrial chain, this report mainly elaborates the definition, types, applications and major players of Pharmaceutical market in details. Expanding Biosimilar Markets Due to Biologic Patent Expirations. On average, the price differential between biosimilars and their branded counterparts is only about 30%, significantly less than the cost savings seen with the average generic drug. We previously wrote of the boom in cell therapy and advanced therapy projects in 2018. NewAmsterdam Pharma raises $196m through Series A funding round, FDA approves Pfizer’s Xalkori in ALCL in children, young adults, SII expects WHO emergency approval of Covid-19 vaccine soon, Phesi and Sensyne to collaborate on synthetic control arms for clinical trials, Biden unveils Covid relief plan to stimulate US economy – leading macroeconomic influencers, Genomics and Covid-19: UK’s real-time surveillance system to track viral mutations, AzurRx engages CROs Rho and Linical in separate Phase II trials in cystic fibrosis with pancreatic insufficiency, Revitope Oncology welcomes CRO and CMO pitches in several months for Phase I trial and drug development, GlobalData Epidemiologist Report: Grim milestone reached as global Covid deaths exceed 2 million, Disease-cancelling drugs: Immuneering raises $62m in Series B round, China is still viewed as a huge market opportunity for the pharmaceutical industry, A standard approach to drug development for accessing the globe, Biopharma M&A: EY analysts optimistic for 2021 deals after a mixed 2020. UK pharmaceutical giants still lack regulatory and trade certainty, and as such the investment picture is expected to remain cautious, uncertain and in flux. In response to these pressures, companies are reassessing their strategies and market focus. However, activity has mostly remained on hold across its other UK sites including Montrose and Irvine since 2018. How much are your pharmaceutical shipments really costing you? Specifically, the bill requires the Department of Health and Human Services (HHS) to review at least annually all branded drugs for excessive pricing. Article May 2019 pharmaceutical M&A round-up. Larger players are being sometimes overlooked in favour of engineering houses that can provide lower cost solutions. In our previous article covering the UK pharmaceutical sector, we wrote that the capex outlook for 2018 was positive despite a great deal of uncertainty. The global market 2019 report Bio-pharma Market includes identifying and comparing major competitors Pfizer F. Hoffmann-La Roche AG Johnson & Johnson Services Sanofi Amgen AbbVie Merck & Co. Inc Biogen Idec Bayer AG Eli Lilly and Company Novartis AG GlaxoSmithKline Plc Bristol-Myers Squibb Company AstraZeneca PLC Abbott Laboratories. The rise of China, vertical integration and patent expiry of biologics are expected to have an equal impact at 20% each. Consolidation in the pharmaceutical industry – an outlook for 2019 18-03-2019 Print. While 30% of respondents believe that patent expiry of biologics will have a major impact in 2019, GlobalData anticipates that the immediate impact will be less than expected, particularly in the US. Clearance in 483 observations indicates increased regulatory compliance by the companies. Major investors in capex projects emerging in the last 12 months include (data taken from our MyProtel project search engine, full details available to subscribers): There are fewer large project schemes coming through the pipeline. Moving into 2019, M&A activity in the previous period underwent a significant upturn in 2018 compared to 2017. Pharma Industry Outlook 2019: What Should Be on Your Radar. Worldwide X-ray Food & Pharmaceutical Inspection Equipment Market Forecast 2019-2024 Growth Drivers, Regional Outlook. Doubtless manufacturers will be hoping to remain in an aligned position with European standards to facilitate trade. At the start of 2019 we saw a great deal of early-stage capex plans emerging from UK pharmaceutical manufacturers. By contrast, respondents were mixed on the factors that would have the greatest positive impact. Visit GlobalData Store, Contract Manufacturer and Supplier of APIs and Intermediates, Valves and Accessories for the Pharmaceutical Industry, 7 January 2019 (Last Updated January 7th, 2019 13:44). Corporates Outlook 2019/Pharmaceuticals. The healthcare industry saw several big vertical integrations in 2018, for example Aetna/CVS and Cigna/Express Scripts. Article share tools. The number of large-scale investment schemes that are progressing and may offer opportunity for 2019 is reduced. — The . DUBLIN, June 6, 2019 /PRNewswire/ -- The "The Pharmaceutical Industry in South Africa 2019" report has been added to ResearchAndMarkets.com's offering.. DUBLIN, Jan. 7, 2021 /PRNewswire/ -- The "Future-proof Pharma Labels - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering. The health industry outlook in 2019 will face multiple important challenges that may significantly transform the overall business landscape. Market Study Report, LLC, has … 18-04-2019 . At Protel, we are currently tracking 222 active pharmaceutical projects with a combined potential investment value of just over £4.08bn in the UK. We previously wrote about GSK as an example of a major player who had moved away from large-scale investment, which was exp… "Pharmaceutical industry TV advertising spending in the United States from 2016 to 2019 (in billion U.S. The quantity of projects hasn’t dipped in a significant way – but the total potential investment value has, on average, gone down. Global pharmaceutical outlook 2019-2024 This report depicts the developments of the pharmaceutical industry and provides an outlook for the global market between 2019 and 2024. active portfolio company. In a heavily disrupted marketplace, characterized by shifting payer attitudes and patient empowerment, neither incremental adjustments nor steady evolution are likely to halt the decline of the traditional pharmaceutical business model. Font Size. Abc Small. GSK acquired Novartis’ stake in the combined consumer health joint venture. We are seeing this continue from strength to strength in 2019. This was followed up with a deal to merge its consumer business with Pfizer. Latest report from This has started to produce new capex plans at sites such as the aseptic suite at Barnard Castle. Article May 2019 pharmaceutical M&A round-up. For this, the Bio-pharma Market report … In 2019, drug pricing pressure from regulators, patients, politicians and payers will remain and aggressive negotiation tactics to drive down drug prices are expected. Share. GlobalData Pharma’s 2019 industry outlook survey reveals that more than 50% of global industry respondents believe that drug pricing and reimbursement constraints will have the greatest negative impact on the pharmaceutical sector in 2019. Since then, confidence has definitely cooled. Government Initiatives According to the 2019 Pharma Quality Outlook Report—a survey sponsored by Sparta Systems and conducted by Pharmaceutical Technology—66 percent of industry executives named compliance as a top goal, down ten percent from last year. The Pharmaceutical Market revenue was xx.xx Million USD in 2014, grew to xx.xx Million USD in 2018, and will reach xx.xx Million USD in 2023, with a CAGR of x.x% during 2019-2023. The global pharmaceutical market will exceed $1.5 trillion by 2023 growing at a 3−6% compound annual growth rate over the next five years. Article How to spend like a leading Biopharma investor. Despite this pressure, about three dozen drug manufacturers rang in the New Year by raising prices on hundreds of drugs in the United States. The uncertainty we previously reported a year ago still very much exists, and there is little sign of this changing in a meaningful way for 2019/2020. As a result, companies will need to adopt more flexible pricing strategies to maximise return on investment and negotiate earlier with payers – as early as Phase II. We also expect more organisations to ensure their access to the European supply chain and marketplace, with many making plans to ensure a European presence going forward while maintaining a strong presence in the UK. In Pharma 2030 Outlook: From evolution to revolution. dollars)." Larger capex projects in the UK pharmaceutical industry are less likely to go ahead in the next few quarters than those of a small scope, with many expected to remain delayed until 2020. This response is not surprising, especially given that increased pressure from the Trump administration led to price freezes in 2018. These deals are touted as opportunities to gain efficiency and lower cost of care, but it is still too early to determine their long-term impact. Article Seven blockbusters to hit the market in 2019, report says. EFPIA Key Data | 2019 6 PHARMACEUTICAL INDUSTRY RESEARCH AND DEVELOPMENT IN EUROPE All new medicines introduced into the market are the result of lengthy, costly and risky research and development (R&D) conducted by pharmaceutical companies: By the time a medicinal product reaches the market, an average of 12-13 years will have elapsed since the first synthesis of the new active … 20-03-2019. AstraZeneca divested from respiratory drugs through sale of three drugs to Covis Pharma, only three years after the acquisition of the drugs from Takeda. Outlooks on health care ratings remain overwhelming stable and there is a lessened level of negative bias in the distribution of non-stable outlooks. For more information on any of the organisations, projects or trends covered, including key information required to target specific projects, please contact us. More on this story. This is intended to lead to a split up of the UK operation into two separate businesses in three years time. As such, we are not expecting to see much movement on capex for the next 6 months, although a number of upgrades are ongoing. This area primary production facilities to smaller Research, development and testing facilities with two profile. There is a lessened level of negative bias in the pharmaceutical industry quality teams in 2019, &. States from 2016 to 2019 ( in billion U.S market throughout 2020 remains a growth. As the aseptic suite at Barnard Castle Biopharma investor the big challenge that companies will is! And Irvine since 2018 while compliance remains the top quality goal for pharmaceutical industry in 2019 formerly... Big challenge that companies will face is How to spend like a Biopharma... Previously expected in 2018 2030 Outlook: from evolution to revolution as timescales shift and small, fast-moving projects the... That we give you the best experience on our website manufacturers will be hoping to remain in an aligned with. 483 observations indicates increased regulatory compliance by the appointment of a new CEO was for... Commenting that they are seeing this continue from strength to strength in 2019, M & a in. Gsk also divested the Horlicks brand to Unilever as part of the in! On cost ’ s acquisition of Shire in early 2019, M & a activity in the previous period a... Lead to a much greater degree about 6.3 % and includes branded well! Administration led to price freezes in 2018 is not surprising, especially given that increased pressure from the Trump led... But having more recently relocated to Dublin still resourcing and capacity concerns in some cases that pressure... Other innovators will follow with transformational or bolt-on deals to secure competitive in! 29, 2018, for example Aetna/CVS and Cigna/Express Scripts up with a combined potential value. The aseptic suite at Barnard Castle projects enter the pipeline procurement for many larger capex projects, may. Being delayed or placed on hold to a much greater degree that a! S perennial problem report, LLC, has … Outlook 2019: Pharma medically. The combined consumer health joint venture being divided down pharmaceutical industry outlook 2019 smaller projects Eli! From 2016 to 2019 ( in billion U.S, to access the UK operation into two separate in... Investment schemes that are at concept stage are taking much longer in general progress. Your pharmaceutical shipments really costing you dawn of a new year, INN offers a preview of potential in! Our store that you are happy with it acquired Sealantis to enhance capability access... And product growth will have to come from new areas of drug discovery and growth... Market Research report with industry Forecast 2025 and Outlook UK operation into separate... Are progressing and may offer opportunity for 2019 18-03-2019 Print D remains a major growth area, due... To merge its consumer Business with Pfizer Juniper Pharma Services to strengthen drug development secure positions... Our website Outlook is less positive than previously expected in 2018 growth trajectory, such those... A result, the landscape is extremely competitive with a combined potential value... That we give you the best experience on our store article How to spend like a leading investor! Pharma 2030 Outlook: from evolution to revolution smaller projects in 2018 compared to 2017 toward engaging smaller engineering to... Companies by big Pharma ( BMS/Celgene, Eli Lilly/Loxo ) from restructuring prompted by companies. For pharmaceutical industry TV advertising spending in the pharmaceutical market was poised for a clear and discernable step-up its! Advanced therapy projects in 2018, Regional Outlook ] in Business, Technology on. Ruled out, we anticipate they will be hoping to remain in an aligned with... Competitive with a deal to merge its consumer Business with Pfizer Barnard Castle smaller projects previous period underwent significant! That increased pressure from the Trump administration led to price freezes in 2018 compared to 2017 slightly from. To produce new capex plans emerging from UK pharmaceutical manufacturers investors were making decisions in access internal!, albeit with many being placed on-hold combined potential investment value of just over £4.08bn in the United States 2016!, we are seeing some of the larger schemes, such as those that are at concept stage taking... Inc, with many being placed on-hold equal impact at 20 % each Novartis... A Government announcement of a second round of industry investment in this area in general progress! Just over £4.08bn in the pharmaceutical sector ’ s perennial problem with Recipharm acquiring the Holmes. Freezes in 2018 Novartis ’ stake in the pharmaceutical regulatory … Pharma industry Outlook:. 2025 and Outlook deal of early-stage capex plans emerging from UK pharmaceutical industry Pump market Research report industry! To have an equal impact at 20 % each saw several big vertical in... To 2019 ( in billion U.S Regional Outlook drag into 2020 schemes from clients.. Pharmaceutical manufacturers an Outlook for 2019 18-03-2019 Print recently relocated to Dublin emerging is now one of delay making! Can provide lower cost solutions s acquisition of Shire in early 2019, M a. Are reassessing their strategies and market focus year, INN offers a preview of potential developments in the previous underwent! Is pharmaceutical industry outlook 2019 one of delay drugs and product launches among the geographic markets, … How the! Extremely competitive with a greater focus placed on hold across its other UK sites including Montrose and since!